Abstract | BACKGROUND & AIMS: METHODS: Thirteen patients with microscopic colitis (7 with subepithelial collagen deposition and 6 without) were treated with eight chewable 262-mg bismuth subsalicylate tablets per day for 8 weeks. Patients recorded the frequency of bowel movements daily. Forty-eight-hour stool collections and flexible sigmoidoscopy with 24 biopsies were performed before and after treatment in each patient. RESULTS: Twelve patients completed the trial. Eleven patients had a resolution of diarrhea and a reduction in fecal weight. The average time to respond was 2 weeks. In 9 patients, colitis resolved. When present before treatment, subepithelial collagen thickening disappeared. Those completing the trial experienced no side effects. Posttreatment follow-up for 7-28 months shows that 9 patients remain well having undergone no further treatment, 2 are well but required retreatment, and 1 has continued diarrhea. CONCLUSIONS:
Bismuth subsalicylate treatment for 8 weeks is safe and well tolerated. This regimen appears to be efficacious for the treatment of microscopic colitis and is worthy of further study in a controlled trial.
|
Authors | K D Fine, E L Lee |
Journal | Gastroenterology
(Gastroenterology)
Vol. 114
Issue 1
Pg. 29-36
(Jan 1998)
ISSN: 0016-5085 [Print] United States |
PMID | 9428215
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Organometallic Compounds
- Salicylates
- bismuth subsalicylate
- Bismuth
|
Topics |
- Administration, Oral
- Adult
- Aged
- Bismuth
(administration & dosage, adverse effects)
- Colitis
(drug therapy, pathology, physiopathology)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Organometallic Compounds
(administration & dosage, adverse effects)
- Salicylates
(administration & dosage, adverse effects)
- Treatment Outcome
|